It has been an incredibly exciting year for research on Modified Citrus Pectin (MCP), and this month, I am proud to announce the publication of the results of over a year’s worth of collaborative study on this unique and powerful cancer-fighting nutraceutical.
As reported in the June issue of Integrative Cancer Therapies, researchers at Columbia University recently evaluated the effects of MCP on human and mouse prostate cancer cell lines. Results showed that MCP inhibits cell proliferation and induces apoptosis (programmed cell death) in both androgen-dependent and androgen-independent cancer cells in a time- and dose-dependent manner.
MCP is derived from the pith of citrus fruit, and is modified to meet specific molecular chain and weight characteristics for maximum absorption. This new study supports the results of previous research on this MCP, which has demonstrated its clinical benefit in patients with advanced solid tumors, as well as its ability to lengthen PSA doubling time in men with recurrent prostate cancer. So how does it do this?
MCP interferes with the binding properties of cancer cell surface proteins called galectins. Rich in a polysaccharide component called galactosyl, MCP binds to galectin proteins and prevents cancerous cells from adhering to each other and to the inner wall of blood vessels, thereby inhibiting both tumor growth and angiogenesis (new blood vessel growth). The results of this most recent study show that MCP also induces apoptosis through the inhibition of the MAPK signal pathway and activation of Caspase-3.
This Columbia University study focused on the effects on one new formulation of MCP in particular—one that boasts an even lower molecular weight range than other forms, which means that a greater relative concentration of the product is able to reach the prostate gland. Again, results show that this particular form of MCP induces cell death in both androgen dependent (hormonal sensitive) and androgen independent (hormonal resistant) prostate cancer. Androgen dependent prostate cancer is the more common type of prostate cancer, and the one more often found in localized and less aggressive disease.
What is most significant here is the ability of this new MCP to induce apoptosis in androgen independent prostate cancer cell lines—the more aggressive cancer that can metastasize and lead to death. Any help in slowing down the progression of this cancer has a direct effect on prolonging the life of these individuals… so I probably don’t have to tell you that this is an incredibly newsworthy discovery.
The anti-metastatic role of MCP is already well established. But the fact that it can have a direct effect on the cancer itself makes it important in prevention, in early stage prostate cancer (which is usually hormonal sensitive-androgen dependent) and in later stage advanced prostate cancer, as well. Its safety and the fact that it doesn’t work via hormonal induced mechanisms of action makes MCP an excellent agent to be used in conjunction with other therapies—while the fact that it has been shown to improve quality of life in clinical research makes it an absolutely essential component of wider cancer protocols.
Needless to say, this is an incredibly exciting development in my ongoing effort to find safe, natural, and effective integrative therapies in the worldwide fight against prostate cancer—and it underscores the vital role that supplements such as MCP can play in your own struggle with this potentially deadly disease. To read more about this study’s details—and to find out more about what it means for you—I invite you to read the entire published article here.
Meanwhile, I look forward to writing about even more groundbreaking new developments in future posts, as we are continuing our research on MCP in prostate cancer as well as in breast cancer with encouraging results, and hope to publish additional papers later this year.
Dr. Isaac Eliaz, a pioneer in the field of integrative medicine since the early 1980's, is a respected author, lecturer, researcher, product formulator and clinical practitioner.
Since 1991 Dr. Eliaz has maintained a busy private practice in northern California that focuses primarily on integrative, holistic protocols for cancer patients. He leads an integrative medical team at Amitabha Clinic in Sebastopol, California with focus on cancer and other chronic ailments.
To learn more, please visit www.dreliaz.org.
Latest posts by Dr. Isaac Eliaz (see all)
- Trouble sleeping? Top tips for a great night’s sleep - June 7, 2016
- 4 ancient medicinal mushrooms fight modern diseases - June 2, 2016
- Ancient wisdom meets modern science in the fight against cancer - March 15, 2016